Open AccessNew aptamer-based approaches for the targeting of cancer associated fibroblast in NSCLC
Author(s) -
G Ciccone,
Oncology “Gaetano Salvatore”,
Maria Luigia Ibba,
Giovanni Coppola,
Giovanni Petrillo,
Silvia Catuogno,
Carla Lucia Esposito,
Consiglio nazionale delle ricerche
Publication year - 2021
Publication title -
sibirskoe medicinskoe obozrenie
Language(s) - English
Resource type - Journals
eISSN - 2500-0136
pISSN - 1819-9496
DOI - 10.20333/25000136-2021-2-83
Subject(s) - aptamer , lung cancer , cancer research , tumor microenvironment , cancer , chemistry , biology , medicine , oncology , tumor cells , microbiology and biotechnology , genetics
The aim of the research. Non-small cell lung cancer (NSCLC) represents about 80 % of all lung cancer cases and is oft en associated with drug resistance, relapses and a poor prognosis. Th erefore, the identifi cation of eff ective therapeutic strategies represents a crucial challenge in oncology. A key limit of conventional anticancer treatments is that they do not target the permissive tumor microenvironment, of which key components are cancer‐associated fibroblasts (CAFs). It has been shown that CAFs are able to regulate malignant progression and drug resistance. However, a detailed characterization of CAF profile and the targeting of their pro-tumor eff ects still remain an ambitious challenge and have a primary importance for the identifi cation of new eff ective therapies. Material and methods. We aimed to develop innovative strategies based on nucleic acid aptamers to address these fundamental issues. Firstly, we applied an aptamer conjugate (named Gint4.T-STAT3), containing a STAT3 siRNA linked to an aptamer binding and inhibiting the PDGFRβ, to specifi cally silence STAT3 reported as a fundamental player in the cross-talk between CAFs and epithelial NSCLC cells. Results. We demonstrated that this molecule eff ectively delivers STAT3 siRNA in NSCLC cells, blocking CAF-induced cell growth and migration in both continous and primary NSCLC coltures. In addition, in order to address CAF specifi c targeting and profi ling, we developed an innovative diff erential cell-SELEX approach by using primary NSCLC CAFs as selection target. Such a strategy allowed the isolation of diff erent aptamers discriminating NSCLC CAFs from normal lung fi broblasts. Th e analyses of aptamer specifi city and functionality is curently ongoing. Conclusion. Our data represent the fi rst ever attempt in CAF targeting using aptamer-based drugs, and can open innovative horizons in the current therapeutic approaches forNSCLC.